Skip to main content
PLOS One logoLink to PLOS One
. 2026 Nov 11;21(11):e0362558. doi: 10.1371/journal.pone.0362558

Predictive factors for risk of chronic evolution in Vogt–Koyanagi–Harada disease at 1 month after pulse steroid therapy

Tetsuya Muto 1,2,3,*, Shoichiro Kusuda 1, Masaaki Sakamoto 1, Shigeki Machida 1, Shinichiro Imaizumi 2, Tetsuju Sekiryu 3
Editor: Robin Haunschild4
PMCID: PMC13754166  PMID: 43013535

Abstract

In this study, we aimed to identify factors for risk of chronic evolution in Vogt–Koyanagi–Harada (VKH) disease at 1 month following pulse steroid therapy. This was a retrospective clinical cohort, single center study. A total of 121 eyes from 61 treatment-naïve patients with acute VKH disease, who underwent pulse steroid therapy and had follow-up for over 12 months were evaluated. Patients were categorized into SGF and non-SGF groups according to fundus outcomes at 12 months after treatment. Anterior chamber morphology was assessed using Pentacam®, while axial length and lens thickness were measured with the IOLMaster 700. Multivariable analysis demonstrated that lower best-corrected visual acuity (BCVA) (p < 0.001) and increased corneal thickness (p = 0.016) at 1 month were significantly associated with the development of SGF. Receiver operating characteristic curve analysis determined optimal cut-off values for predicting SGF as a logarithmic BCVA greater than −0.040 and a corneal thickness exceeding 574.500 µm. The corresponding Youden index values were 0.291 for BCVA and 0.244 for corneal thickness. Elevated logarithmic BCVA values and increased corneal thickness at 1 month after treatment were identified as risk factors for the subsequent SGF development. Applying higher cut-off values for these factors may facilitate more targeted therapeutic strategies in patients with VKH disease.

Introduction

Vogt–Koyanagi–Harada (VKH) disease is a bilateral granulomatous panuveitis with potential multisystem involvement. It is a T-cell-mediated autoimmune disorder that occurs in genetically susceptible individuals, in which cytotoxic T-cells target melanocytes [1]. As melanocytes are widely distributed throughout the body, systemic manifestations such as fever meningitis-like symptoms, headache, paresthesia of hair, and general malaise often precede the onset of ocular symptoms. The disease can develop across a wide age range, from infancy to older adulthood, but is reported more frequently in females [2–8]. Adequate inhibition of inflammation during the early stage of the disease is important for preventing recurrence and the persistence of inflammation during later progressive stages.

In Japan, corticosteroid pulse therapy consisting of 500–1000 mg of intravenous methylprednisolone administered over 3 days, followed by several months of oral corticosteroids, has been widely implemented for many years [2–8]. However, the recurrence rate of VKH disease remains approximately 25%, even with pulse steroid therapy [2–5]. Urzura et al. reported that chronic recurrent VKH disease is more refractory to treatment and is associated with a higher rate of complications [9]. Thus, strategies aimed at reducing disease recurrence are essential.

Several studies have indicated a strong association between disease recurrence and the development of sunset glow fundus (SGF) [2,3,6]. Thus, preventing SGF is an essential objective. El Asrar et al. showed that combining mycophenolate mofetil therapy with systemic corticosteroids was effective for reducing the risk of SGF [10].

We also recognized the importance of identifying predictive factors for the development of SGF [2]. Clarifying these predictive factors could allow for more effective treatment management. Hirooka et al. highlighted that central choroidal thickness, measured 1 week after systemic corticosteroid therapy, was a key indicator in treatment-naïve patients with VKH disease [6]. They reported a cut-off value of 410 μm for predicting SGF development. Although attempts have been made to identify predictive factors at the initial patient visit, the sensibility and specificity of these early indicators do not always have enough value [2].

The aim of this study was to identify factors quantifiable at 1 month after pulse steroid therapy, as well as at the initial patient visit, that could predict the risk of chronic evolution 12 months post-treatment in patients with acute VKH disease.

Materials and methods

This retrospective clinical cohort study included 61 treatment-naïve patients with VKH disease totaling 121 eyes. The mean age of participants was 45.0 ± 14.3 years (range 13–77 years) at Dokkyo Medical University Saitama Medical Center between April 2015 and October 2024. All participants were followed up for over 12 months after initiating pulse steroid therapy.

The type of VKH disease was classified according to recent diagnostic criteria [11]. The older revised diagnostic criteria [12] may have certain disadvantages because recent criteria have higher diagnostic sensitivity [11].

Patients diagnosed at the initial visit with chronic VKH disease, amblyopia, senile cataract, senile dementia, ischemic optic neuropathy, high myopia (less than −8 diopters), or hypermetropia (greater than +5 diopters) were excluded from this study.

Pulse steroid therapy was initiated with intravenous methylprednisolone (Solu-Medrol; Pfizer, NY, USA) at a dose of 1,000 mg/day for 3 days, followed by oral prednisolone (Predonine; Shionogi, Osaka, Japan). Oral prednisolone was started at 40 mg/day and tapered by 5 mg/day every 3 − 4 weeks, as previously described [2,3]. Although one patient was 13 years old, her body weight (48 kg) allowed for the administration of the standard steroid regimen. Patients with recurrence limited to the anterior segment were treated with 0.1% fluorometholone ophthalmic suspension (Santen, Osaka, Japan) or Sanbetason ophthalmic and otorhinologic solution (Santen, Osaka, Japan). Patients with recurrence in the posterior segment were treated with oral corticosteroids or sub-Tenon triamcinolone acetonide injections. If anterior inflammation progressed to the chronic type and became resistant to steroid therapy, adalimumab was administered.

During therapy, secondary cataract development was limited to the posterior subcapsular forms and affected best-corrected visual acuity (BCVA).

Written informed consent for treatment was obtained from all participants. The study protocol adhered to the Declaration of Helsinki and was approved by the Institutional Review Board of Dokkyo Medical University Saitama Medical Center (#25114). Informed consent for publication was waived due to the retrospective design of the study. The data were accessed for research purposes on March 28, 2026

Biomarker measurement

At the initial visit, all patients underwent comprehensive ophthalmologic evaluations, including standardized refraction, BCVA measurement using a Landolt ring, slit-lamp biomicroscopy, anterior segment analysis, axial length (AL) measurement, optical coherence tomography (OCT), and color fundus photography. Decimal BCVA values were converted to the logarithm of the minimal angle of resolution.

Fluorescein angiography (FAG) and indocyanine green angiography (ICGA) were performed on 54 patients. Four patients did not undergo urgent FAG or ICGA because recent angiographic records from previous hospitalizations were available, while three patients did not undergo the procedures due to emergency admissions. Refractive status was assessed using an autorefractometer (KR-7100; Topcon Corp., Tokyo, Japan), and the spherical equivalent (SE) was calculated as the spherical power plus half of the cylindrical power.

Anterior chamber parameters, including volume (ACV), central depth (ACD), peripheral depth, angle (ACA), corneal thickness, and pupil diameter were measured using PentacamⓇ software. All anterior segment measurements were obtained with a contracted pupil. Peripheral ACD was calculated as the mean of four points located 3 mm from the pupil center. AL and lens thickness were measured using the IOLMaster 700 (Carl Zeiss Meditec AG, Jena, Germany). Retinal morphology was assessed using spectral-domain OCT (RS-3000 Advance, Nidek Corp., Japan), with scans obtained through both horizontal and vertical foveal passes. Average retinal foveal thickness (RFT) was calculated as the mean of these horizontal and vertical thickness measurements. Swept-source OCT (SS-OCT; PLEX Elite 9000, Carl Zeiss Meditec AG, Jena, Germany) was used to measure choroidal foveal thickness (CFT), defined as the distance from the outer border of the retinal pigment epithelium to the inner scleral border at the fovea. Values exceeding 800 μm were limited by image resolution. All OCT images were independently analyzed by a blinded author (M.S.).

A single investigator (TM) assessed the ocular findings at approximately monthly intervals, and routinely determined the onset of SGF based on the appearance of the orange-red fundus discoloration that had not been present at the visit 1 month earlier. The presence of SGF in each eye was subsequently reconfirmed by reviewing the color fundus photographs.

Patients were stratified into two groups based on the presence or absence of SGF at 12 months, designated as the SGF and a non-SGF groups. Correlations between measurements obtained at the initial visit and at 1-month, as well as their associations with fundus outcomes at 12-months, were analyzed.

Statistical analysis

Descriptive data are presented as means ± standard deviations. To evaluate the statistical significance of changes over time after the initiation of pulse steroid therapy, a one-way repeated-measures ANOVA was conducted, followed by Tukey’s post hoc tests. Generalized estimating equations (GEEs) were used, with Bonferroni correction applied for multiple comparisons. The unpaired t-test was used to compare the SGF and non-SGF groups at each time point. Stepwise multivariable analysis, with a p-value threshold of 0.2, was applied to identify factors associated with 12-month fundus outcomes. These outcomes included BCVA, ACV, ACD (also peripheral), corneal thickness, SE and changes in these parameters from the initial visit to 1 month, difference of ACV from initial visit to 1 month post-treatment, as well as ACA, pupil diameter, AL, RFT, and CFT. StatMate version V for Macintosh (ATMS, Tokyo, Japan) was used to perform one-way repeated-measures ANOVA, Tukey’s tests, unpaired t-tests, and chi-square tests. JMP 16 Pro (SAS Institute, Inc., Cary, NC, USA) was employed for multivariable analysis, and IBM SPSS Statistics 29.0.0 (IBM Corp., Tokyo, Japan) was used for receiver operating characteristic (ROC) analysis, GEEs and Bonferroni adjusted comparisons. Optimal cut-off values in ROC analyses were determined using the Youden index. Statistical significance was set at p < 0.05.

Results

Table 1 presents the demographic characteristics of patients in the SGF and non-SGF groups at the initial visit. No significant differences were observed between groups for any demographic factors.

Table 1. Demographic characteristics of patients with VKH at the initial visit, categorized by subsequent SGF development.

  SGF Non-SGF p value
At the initial visit in 61 patients    
Age (years) 46.1 ± 12.8 43.8 ± 16.5 0.56
Gender (male/female) 15/17 14/15 0.91
Body weight (kg) 63.6 ± 14.7 61.0 ± 13.0 0.48
From symptom onset to initial visit (days) 19.3 ± 42.8 10.1 ± 7.9 0.24
Meningismus (yes/no) 24/8 23/6 0.69
Recent revised diagnostic criteria

(variant 1/variant 2)
28/4 23/6 0.61
Smoking condition    
(smoker/past smoker/non-smoker) 11/2/19 8/7/14 0.14
Synechia between lens and iris (yes/no) 10/53 4/54 0.21
HbA1c (%) 5.91 ± 1.39 5.59 ± 0.43 0.22

Abbreviations: HbA1c, glycated hemoglobin; SGF, sunset glow fundus.

Table 2 summarizes the clinical characteristics of 121 eyes from 61 patients who were followed for more than 12 months after pulse steroid therapy. The non-SGF group had fewer cases of secondary cataracts and a lower disease recurrence rate within 12 months than the SGF group. No significant differences in BCVA were observed between the groups.

Table 2. Clinical characteristics of patients observed for >12 months after pulse steroid therapy in the SGF and non-SGF groups.

  SGF Non-SGF p value
At 12 months in 61 patients    
BCVA at 12 months –0.069 ± 0.042 –0.043 ± 0.094 0.053
Secondary cataract (yes/no) 6/57 0/58 0.046
Recurrence experience (yes/no) 13/19 2/27 <0.01

Abbreviations: BCVA, best-corrected visual acuity; SGF, sunset glow fundus.

In the multivariate analysis, lower BCVA (p < 0.001) and greater cornea thickness (p = 0.016), were significantly associated with SGF at 12 months. Table 3 shows the cut-off values for BCVA and corneal thickness, determined by ROC curve analysis for SGF at 12 months. Although the sensitivity values for both factors were below 0.5, the specificity values exceeded 0.862. The corresponding Youden index values for each factor were less than 0.3.

Table 3. Cut-off values determined by ROC curves for SGF at 12 months.

  Cut-off value Sensitivity Specificity Youden index
BCVA –0.040 0.429 0.862 0.291
Corneal thickness (µm) 574.5 0.365 0.879 0.244

Abbreviations: BCVA, best-corrected visual acuity.

Fig 1 illustrates the chronological changes in average biomarker levels in both groups. The biomarkers included BCVA, anterior-chamber parameters, SE, AL, lens thickness, RFT, and CFT after the initiation of pulse steroid therapy. BCVA values increased significantly over time course in both groups (p < 0.001) according to one-way repeated-measures ANOVA (Fig 1a). ACV in the SGF group also increased significantly over time (p < 0.01), whereas ACV in the non-SGF group remained unchanged (p = 0.16) (Fig 1b). Central ACD values increased significantly over time in both groups (SGF group: p < 0.001, non-SGF group: p < 0.01) (Fig 1c). Peripheral ACD showed a similar pattern (SGF group: p < 0.001, non-SGF group: p < 0.05) (Fig 1d). ACA increased significantly increased in the SGF group (p < 0.05), but remained largely unchanged in the non-SGF group (p = 0.062) (Fig 1e). Pupil diameter decreased significantly over time in both groups (p < 0.05) (Fig 1f). Corneal thickness declined significantly over time in the SGF group (p < 0.05) but remained stable in the non-SGF group (p = 0.71) (Fig 1g). A similar trend was observed for SE in the non-SGF group, while the SGF group showed no significant changes (p = 0.40) (Fig 1h). AL increased significantly in the SGF group (p < 0.05) but showed no significant change in the non-SGF group (p = 0.089) (Fig 1i). Lens thickness remained stable over time (SGF group: p = 0.54, non-SGF group: p = 0.74) (Fig 1j). Both RFT and CFT decreased significantly over the observation period in both groups according to one-way repeated-measures ANOVA (p < 0.001) (Fig 1k and 1l).

Fig 1. (a) Longitudinal changes in BCVA, as the logarithm of the minimal angle of resolution for both the SGF and non-SGF groups at pretreatment and months 1, 6, and 12, with significant differences at pretreatment (p < 0.05) and month 1 (p < 0.001).

Fig 1

(b) ACV at pretreatment and 1, 6, and 12 months with significant differences at pretreatment (p < 0.05) and month at 12 months post-treatment (p < 0.05). (c) Central ACD at pretreatment and at 1, 6, and 12 months post-treatment, without significant differences. (d) Peripheral ACD at pretreatment and at 1, 6, and 12 months post-treatment, with significant differences at pretreatment (p < 0.05) and 12 months (p < 0.05). (e) ACA at pretreatment and at 1, 6, and 12 months post-treatment, without significant differences. (f) Pupil diameter at pretreatment and at 1, 6, and 12 months post-treatment, with significant differences at pretreatment (p < 0.05), 1 month (p < 0.05), and 12 months (p < 0.05). (g) Corneal thickness at pretreatment and at 1, 6, and 12 months post-treatment, showing significant differences at pretreatment (p < 0.001) and at 1 month (p < 0.05), 6 months (p < 0.01), and 12 months (p < 0.05). (h) SE was at pretreatment and at 1, 6, and 12 without significant difference. (i) AL at pretreatment and at 1, 6, and 12 months post-treatment, without significant differences. (j) Lens thickness at pretreatment and at 1, 6, and 12 months post-treatment, without significant differences. (k) RFT at pretreatment and at 1, 6, and 12 months post-treatment, without significant differences according to the unpaired t-test. (l) CFT at pretreatment and at 1, 6, and 12 months post-treatment, with significant differences at pretreatment (p < 0.01), and 1 month (p < 0.05) according to the unpaired t-test. Abbreviations: ACA, anterior chamber angle; ACD, anterior chamber depth; ACV, anterior chamber volume; AL, axial length; BCVA, best-corrected visual acuity; CFT, choroidal foveal thickness; RFT, retinal foveal thickness; SE, spherical equivalent.

Fig 2 illustrates the chronological changes in mean biomarker values in both groups, as analyzed using GEEs. BCVA improved significantly over time in both groups (Fig 2a). ACV (Fig 2b) and central ACD values (Fig 2c) also increased significantly over time in both groups. Peripheral ACD showed a similar pattern (Fig 2d). ACA increased significantly in the non-SGF group remained largely unchanged in the SGF group (Fig 2e). Pupil diameter (Fig 2f) and corneal thickness (Fig 2g) remained unchanged over time in both groups. SE decreased significantly in the SGF group, but showed minimal change in the non-SGF group (Fig 2h). AL increased significantly in both groups (Fig 2i). Lens thickness decreased significantly over time in the non-SGF group, but remained stable in the SGF group (Fig 2j). Both RFT and CFT decreased significantly over the observation period in both groups according to the GEE analysis (p < 0.001) (Fig 2k and 2l).

Fig 2. (a) Longitudinal changes in BCVA, as the logarithm of the minimum angle of resolution for the SGF and non-SGF groups at pretreatment and at 1, 6, and 12 months post-treatment.

Fig 2

A significant difference was observed at 1 month (p < 0.01). (b) ACV at pretreatment and at 1, 6, and 12 months post-treatment. without significant differences. (c) Central ACD at pretreatment and at 1, 6, and 12 months post-treatment. No significant differences were observed. (d) Peripheral ACD at pretreatment and at 1, 6, and 12 months post-treatment. No significant differences were observed. (e) ACA at pretreatment and at 1, 6, and 12 months post-treatment. No significant differences were observed. (f) Pupil diameter at pretreatment and at 1, 6, and 12 months post-treatment. No significant differences were observed. (g) Corneal thickness at pretreatment and at 1, 6, and 12 months post-treatment. Significant differences were observed at pretreatment (p < 0.001). (h) SE at pretreatment and at 1, 6, and 12 months post-treatment. No significant differences were observed. (i) AL at pretreatment and at 1, 6, and 12 months post-treatment. No significant differences were observed. (j) Lens thickness at pretreatment and at 1, 6, and 12 months post-treatment. No significant differences were observed. (k) RFT at pretreatment and at 1, 6, and 12 months post-treatment. No significant differences were observed. (l) CFT at pretreatment and at 1, 6, and 12 months post-treatment. No significant differences were observed. Abbreviations: ACA, anterior chamber angle; ACD, anterior chamber depth; ACV, anterior chamber volume; AL, axial length; BCVA, best-corrected visual acuity; CFT, choroidal foveal thickness; RFT, retinal foveal thickness; SE, spherical equivalent.

Fig 3 presents a comparative analysis of BCVA and corneal thickness between the SGF and non-SGF groups. The cut-off values for these parameters were determined using ROC analysis (Fig 3a and 3b).

Fig 3. (a) Comparison of BCVA between the SGF and non-SGF groups at 1 month after pulse steroid therapy.

Fig 3

The determined cut-off value for BCVA was –0.040. (b) Comparison of corneal thickness between the groups at 1 month post-treatment. The cut-off value for corneal thickness was 574.500 μm between the two groups. Abbreviations: BCVA, best-corrected visual acuity; SGF, sunset glow fundus.

Discussion

In our previous study, we identified predictive factors for SGF at the initial visit [2]. However, these factors did not consistently show high sensitivity and specificity [2]. In this study, we aimed to identify more reliable predictive factors with higher diagnostic values. Using data collected at the initial visit and 1 month post-treatment, we identified only two factors with a Youden index below 0.3. Although these two factors may have some clinical utility, they have limited predictive power. Future research should focus on identifying predictive factors with a Youden index exceeding 0.5 to provide stronger clinical guidance. The differences observed between these time points appeared to be significant in the SGF group, as illustrated in Fig 1a–1d, 1g, and 1h. Based on these observations, we conducted multivariate analyses of the changes in BCVA, ACV, central and peripheral ACD, corneal thickness, and SE. However, none of these changes were significantly associated with SGF.

Corneal thickness at the initial visit and 1 month post-treatment was associated with SGF in the previous [2] and present studies, respectively. To the best of our knowledge, only two reports have examined the relationship between these two parameters [2,13], based on searched of the PubMed database (key words: “Vogt–Koyanagi–Harada” “corneal thickness”; search years, 1950–2025) and the CiNii Research database (keywords: “Vogt–Koyanagi–Harada”, “corneal thickness”; search years, 1990–2025). Hamano et al. reported that central corneal thickness decreased significantly after treatment and correlated with flare values, as measured by anterior SS-OCT (CASIA-2) [13]. These findings suggest that the association between VKH disease and corneal morphology is clinically important, and further research may yield additional insights in this field.

No previous studies have reported an association between SGF and visual acuity measured at 1 month after therapy, based on searches of the PubMed database (keywords: “Vogt–Koyanagi–Harada,” “sunset glow fundus,” “visual acuity”; search years: 1950–2025) and the CiNii Research database (keywords: “Vogt–Koyanagi–Harada,” “sunset glow fundus,” “visual acuity”; search years: 1990–2025). However, several reports have documented such associations at the initial visit [14–16]. Future studies are warranted to examine the relationships between SGF development and visual acuity measured on day 1 and weeks 1 and 2 after therapy.

The Youden index, defined as maxc {sensitivity(c)+specificity(c)-1}, is one of the most widely used metrics because it integrates naturally within the ROC framework [17]. Its values range from 0 to 1, with a value of 1 indicating perfect discriminatory performance, while a value of 0 indicates that the biomarker performs no better than chance [18]. The clinical relevance of the Youden index is well illustrated in the context of adenoviral conjunctivitis. Morozumi et al. reported sensitivity and specificity values exceeding 90% for a recently developed immunochromatographic assay for adenovirus detection [19], indicating excellent diagnostic performance. In the future studies, we aim to identify SGF-related predictors in patients with VKH disease that achieve comparable levels of accuracy.

Based on our findings, we identified, to a certain extent, cases with a higher likelihood of developing SGF. Establishing an appropriate management method for such cases is therefore clinically important. However, it is uncertain whether the simple increase in corticosteroid dosage, the addition of sub-tenon triamcinolone acetonide injection [20], combination therapy with an immunosuppressive agent [7,10,20,21] or biologicals [14,22] provides the greatest benefit. Future studies are needed to clarify the most effective treatment method and to determine whether optimized management can reduce SGF incidence We hope coping methods will be made clear in the future and reduce SGF incidence.

It is now well recognized that adequate of early immunosuppression plays a critical role in preventing the chronic evolution of VKH disease. Tsubota et al. reported no significant difference in clinical efficacy between conventional pulse steroid therapy (1,000 mg/day of intravenous methylprednisolone for 3 days) and half-pulse steroid therapy (500 mg/day of intravenous methylprednisolone for 3 days) for VKH disease [8], concluding that half-pulse steroid therapy may reduce the risk of corticosteroid-related adverse effects [8]. They demonstrated that differences in initial steroid dosing strategies can significantly influence clinical outcomes, highlighting the importance of treatment-related variables in determining long-term disease progression [8]. Because pulse steroid therapy is associated with several adverse effects [23], their study is noteworthy in suggesting a strategy to reduce this risk [8].

Yang et al. reported that meningismus, tinnitus, dysacusis, and high sensitivity to touch of the hair were observed in 42.3%, 30.2%, 7.5%, and 6.6% of the pediatric VKH patients (age of ≤ 16 years), respectively, whereas a significantly higher proportion of these manifestations was observed in adult (16 <age < 65 years) and elderly (age of ≥ 65 years) VKH patients (all p < 0.001) [24]. Furthermore, they concluded that the pediatric or elderly VKH patients showed a favourable visual prognosis, whereas the adult VKH patients were associated with a higher risk of poor visual outcomes [24]. Thus, extraocular manifestations might have been strongly associated with VKH disease progression [24,25]. However, history-taking was insufficient, and only meningismus was confirmed in all patients. This study focused exclusively on ocular parameters. If history-taking were sufficient, this study would be more informative.

The present study has several limitations. First, patients were classified into the SGF and non-SGF groups on the basis of fundus findings 12 months after treatment initiation. In clinical practice, a definitive diagnosis of SGF often requires observation beyond 12 months, particularly in patients who receive aggressive early immunosuppressive therapy. Therefore, classification of the SGF and non-SGF groups based on fundus findings obtained at a later time point may be more appropriate. Second, we assessed predictive factors at 1 month after pulse steroid therapy. At this stage, patients are still in the early recovery phase of acute VKH disease, and inflammatory activity may fluctuate depending on treatment response, the tapering schedule, and individual immune dynamics. Therefore, it may be unrealistic to assume that a single measurement obtained at this time point can serve as a reliable predictor of a chronic structural outcome such as SGF. Third, the Youden index values for both BCVA and corneal thickness were <0.3, and the sensitivity values for both predictors were <0.5, as shown in Table 3. These findings suggest that the proposed predictors have limited clinical utility. Fourth, corneal thickness may represent a nonspecific marker of systemic or ocular inflammation rather than a disease-specific predictor. It was not possible to distinguish between these possibilities in the present study. Fifth, because we did not perform an a priori sample size calculation, the possibility of insufficient statistical power and the absence of significant differences cannot be excluded. To further assess the adequacy of the sample size, we performed a post hoc power analysis using the R software [26]. Based on the Youden index threshold of 0.5 and specificity of 0.862 observed in the present study, the sensitivity was calculated to be 0.638 using the following formula: Youden index = sensitivity + specificity − 1 [17]. Based on these estimates, the required sample size was calculated to be 538 eyes. Although this post hoc analysis does not replace an a priori sample size calculation, it provides additional information regarding the sample size adequacy in this study. Thus, further well-designed prospective clinical studies with an appropriate a priori sample size calculation are needed to validate our findings.

In conclusion, this study identified two risk factors at 1 month post-treatment, along with their corresponding cut-off values, that are associated with the risk of chronic evolution. These findings may support more informed clinical decision-making in patients with VKH disease, particularly those presenting with BCVA and corneal thickness values exceeding the identified thresholds. Our future objectives include identifying more reliable predictive factors and establishing management strategies for cases exceeding the identified cut-off values.

Acknowledgments

The authors thank Enago for their assistance with English language editing. We also extend our gratitude to Yasuo Haruyama of the Department of Public Health, School of Medicine, Dokkyo Medical University, for supporting the statistical analyses.

Data Availability

All relevant data are within the manuscript.

Funding Statement

The author(s) received no specific funding for this work.

References

  • 1.Dutta Majumder P, Sadhu S, González-López JJ, Mochizuki M. A COVID-19 perspective of Vogt-Koyanagi-Harada disease. Indian J Ophthalmol. 2023;71(6):2587–91. doi: 10.4103/IJO.IJO_172_23 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Muto T, Sakamoto M, Machida S, Imaizumi S, Sekiryu T. Predictive factors at initial visit for sunset glow fundus in Vogt-Koyanagi-Harada disease. Sci Rep. 2025;15(1):24302. doi: 10.1038/s41598-025-08252-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Muto T, Sakamoto M, Kusuda S, Haruyama Y, Machida S, Imaizumi S, et al. Effect of the COVID-19 pandemic on Vogt-Koyanagi-Harada disease. Sci Rep. 2024;14(1):13211. doi: 10.1038/s41598-024-63957-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Iwahashi C, Okuno K, Hashida N, Nakai K, Ohguro N, Nishida K. Incidence and clinical features of recurrent Vogt-Koyanagi-Harada disease in Japanese individuals. Jpn J Ophthalmol. 2015;59(3):157–63. doi: 10.1007/s10384-015-0377-1 [DOI] [PubMed] [Google Scholar]
  • 5.Nakayama M, Keino H, Watanabe T, Okada AA. Clinical features and visual outcomes of 111 patients with new-onset acute Vogt-Koyanagi-Harada disease treated with pulse intravenous corticosteroids. Br J Ophthalmol. 2019;103(2):274–8. doi: 10.1136/bjophthalmol-2017-311691 [DOI] [PubMed] [Google Scholar]
  • 6.Hirooka K, Saito W, Namba K, Mizuuchi K, Iwata D, Hashimoto Y, et al. Early post-treatment choroidal thickness to alert sunset glow fundus in patients with Vogt-Koyanagi-Harada disease treated with systemic corticosteroids. PLoS One. 2017;12(2):e0172612. doi: 10.1371/journal.pone.0172612 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Ono T, Goto H, Sakai T, Nitta F, Mizuki N, Takase H, et al. Comparison of combination therapy of prednisolone and cyclosporine with corticosteroid pulse therapy in Vogt-Koyanagi-Harada disease. Jpn J Ophthalmol. 2022;66(2):119–29. doi: 10.1007/s10384-021-00878-w [DOI] [PubMed] [Google Scholar]
  • 8.Tsubota K, Goto H, Asakage M, Kinoshita Y, Nonaka R, Wakatsuki K, et al. Comparative study of efficacy and safety of pulse versus half-pulse steroid therapy for Vogt-Koyanagi-Harada Disease. Jpn J Ophthalmol. 2025;69(5):805–12. doi: 10.1007/s10384-025-01213-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Urzua CA, Herbort C Jr, Valenzuela RA, Abu El-Asrar AM, Arellanes-Garcia L, Schlaen A, et al. Initial-onset acute and chronic recurrent stages are two distinctive courses of Vogt-Koyanagi-Harada disease. J Ophthalmic Inflamm Infect. 2020;10(1):23. doi: 10.1186/s12348-020-00214-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Abu El-Asrar AM, Dosari M, Hemachandran S, Gikandi PW, Al-Muammar A. Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of “sunset glow fundus” in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease. Acta Ophthalmol. 2017;95(1):85–90. doi: 10.1111/aos.13189 [DOI] [PubMed] [Google Scholar]
  • 11.Yang P, Zhong Y, Du L, Chi W, Chen L, Zhang R, et al. Development and evaluation of diagnostic criteria for Vogt-Koyanagi-Harada disease. JAMA Ophthalmol. 2018;136(9):1025–31. doi: 10.1001/jamaophthalmol.2018.2664 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Read RW, Holland GN, Rao NA, Tabbara KF, Ohno S, Arellanes-Garcia L, et al. Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: report of an international committee on nomenclature. Am J Ophthalmol. 2001;131(5):647–52. doi: 10.1016/s0002-9394(01)00925-4 [DOI] [PubMed] [Google Scholar]
  • 13.Hamano Y, Maruyama K, Oie Y, Maeda N, Koh S, Hashida N, et al. Novel corneal morphological alterations in Vogt-Koyanagi-Harada disease. Jpn J Ophthalmol. 2022;66(4):358–64. doi: 10.1007/s10384-022-00914-3 [DOI] [PubMed] [Google Scholar]
  • 14.Feng H, Chen W, Yang J, Kong H, Li H, He Y, et al. Predictive factors and adalimumab efficacy in managing chronic recurrence Vogt-Koyanagi-Harada disease. BMC Ophthalmol. 2024;24(1):238. doi: 10.1186/s12886-024-03511-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Maruyama K, Noguchi A, Shimizu A, Shiga Y, Kunikata H, Nakazawa T. Predictors of recurrence in Vogt-Koyanagi-Harada disease. Ophthalmol Retina. 2018;2(4):343–50. doi: 10.1016/j.oret.2017.07.016 [DOI] [PubMed] [Google Scholar]
  • 16.Jin K, Liang A, Song H, Xiao F, Gao F, Han X, et al. A novel risk stratification-based immunomodulatory treatment strategy for Vogt-Koyanagi-Harada disease. Am J Ophthalmol. 2024;262:25–33. doi: 10.1016/j.ajo.2024.01.035 [DOI] [PubMed] [Google Scholar]
  • 17.Yin J, Tian L. Joint confidence region estimation for area under ROC curve and Youden index. Stat Med. 2014;33(6):985–1000. doi: 10.1002/sim.5992 [DOI] [PubMed] [Google Scholar]
  • 18.Attwood K, Tian L. Confidence interval estimation of the Youden index and corresponding cut-point for a combination of biomarkers under normality. Commun Stat Theory Methods. 2022;51(2):501–18. doi: 10.1080/03610926.2020.1751852 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Morozumi M, Shimizu H, Matsushima Y, Mitamura K, Tajima T, Iwata S, et al. Evaluation of new immunochromatographic assay kit for adenovirus detection in throat swab: comparison with culture and real-time PCR results. J Infect Chemother. 2014;20(5):303–6. doi: 10.1016/j.jiac.2014.01.005 [DOI] [PubMed] [Google Scholar]
  • 20.Nakayama M, Okada AA, Hayashi I, Ando Y, Watanabe T, Keino H. A COVID-19 risk reduction strategy for the treatment of acute Vogt-Koyanagi-Harada disease utilizing the antiviral potential of cyclosporine. Ocul Immunol Inflamm. 2023;31(2):462–7. doi: 10.1080/09273948.2022.2028293 [DOI] [PubMed] [Google Scholar]
  • 21.Concha-Del Río LE, Gómez L, Arellanes-García L. Corticotherapy vs. Corticotherapy Plus Immunosuppressive Therapy In Acute Vogt-Koyanagi-Harada Disease. Arch Soc Esp Oftalmol (Engl Ed). 2018;93(5):225–30. doi: 10.1016/j.oftal.2017.09.010 [DOI] [PubMed] [Google Scholar]
  • 22.Shinagawa M, Namba K, Mizuuchi K, Iwata D, Hase K, Suzuki K, et al. The steroid-sparing effect of adalimumab in the treatment for the recurrent phase of Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm. 2023;31(3):501–5. doi: 10.1080/09273948.2022.2037657 [DOI] [PubMed] [Google Scholar]
  • 23.Koncak G, Tolunay O, Unal A, Celiloglu C, Celik U. Short-term side effects of pulse steroid treatment in children. J Coll Physicians Surg Pak. 2022;32(2):262–4. doi: 10.29271/jcpsp.2022.02.262 [DOI] [PubMed] [Google Scholar]
  • 24.Yang P, Liao W, Pu Y, Zhong Z, Wang H, Yu Q, et al. Vogt-Koyanagi-Harada disease in pediatric, adult and elderly: Clinical characteristics and visual outcomes. Graefes Arch Clin Exp Ophthalmol. 2023;261(9):2641–50. doi: 10.1007/s00417-023-06058-5 [DOI] [PubMed] [Google Scholar]
  • 25.Yang P, Ren Y, Li B, Fang W, Meng Q, Kijlstra A. Clinical characteristics of Vogt-Koyanagi-Harada syndrome in Chinese patients. Ophthalmology. 2007;114(3):606–14. doi: 10.1016/j.ophtha.2006.07.040 [DOI] [PubMed] [Google Scholar]
  • 26.R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2025. Available from: https://www.R-project.org/ [Google Scholar]

Decision Letter 0

Robin Haunschild

26 Apr 2026

Dear Dr. Muto,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jun 10 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

  • A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only  the individual author can complete the verification step; PLOS staff cannot  verify ORCID iDs on behalf of authors.

We look forward to receiving your revised manuscript.

Kind regards,

Robin Haunschild

Academic Editor

PLOS One

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following in the Acknowledgments Section of your manuscript:

“The authors received no external funding or financial support.”

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

“The author(s) received no specific funding for this work.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

3. Please include a separate caption for each figure in your manuscript.

4. We note that Figure 1 in your submission contain copyrighted images. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For more information, see our copyright guidelines: http://journals.plos.org/plosone/s/licenses-and-copyright.

We require you to either (1) present written permission from the copyright holder to publish these figures specifically under the CC BY 4.0 license, or (2) remove the figures from your submission:

1. You may seek permission from the original copyright holder of Figure(s) [#] to publish the content specifically under the CC BY 4.0 license.

We recommend that you contact the original copyright holder with the Content Permission Form (http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf) and the following text:

“I request permission for the open-access journal PLOS ONE to publish XXX under the Creative Commons Attribution License (CCAL) CC BY 4.0 (http://creativecommons.org/licenses/by/4.0/). Please be aware that this license allows unrestricted use and distribution, even commercially, by third parties. Please reply and provide explicit written permission to publish XXX under a CC BY license and complete the attached form.”

Please upload the completed Content Permission Form or other proof of granted permissions as an "Other" file with your submission.

In the figure caption of the copyrighted figure, please include the following text: “Reprinted from [ref] under a CC BY license, with permission from [name of publisher], original copyright [original copyright year].”

2. If you are unable to obtain permission from the original copyright holder to publish these figures under the CC BY 4.0 license or if the copyright holder’s requirements are incompatible with the CC BY 4.0 license, please either i) remove the figure or ii) supply a replacement figure that complies with the CC BY 4.0 license. Please check copyright information on all replacement figures and update the figure caption with source information. If applicable, please specify in the figure caption text when a figure is similar but not identical to the original image and is therefore for illustrative purposes only.

5. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously? -->?>

Reviewer #1: Yes

Reviewer #2: No

**********

3. Have the authors made all data underlying the findings in their manuscript fully available??>

The PLOS Data policy

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #1: Yes

Reviewer #2: No

**********

Reviewer #1: This manuscript investigates predictive factors for the development of sunset glow fundus (SGF) in patients with Vogt–Koyanagi–Harada (VKH) disease, focusing on parameters measured at 1 month after pulse steroid therapy. The study includes a relatively well-defined cohort of treatment-naïve patients with at least 12 months of follow-up, and the attempt to identify early predictive indicators is clinically relevant. However, several conceptual and methodological concerns limit the validity of the conclusions. In particular, the definition and timing of SGF assessment raise important issues that must be addressed before the manuscript can be considered for publication.

1) The most critical concern relates to the diagnostic definition and temporal interpretation of sunset glow fundus. In this study, patients were classified into SGF and non-SGF groups based on fundus findings at 12 months after treatment initiation. However, the manuscript implicitly assumes that SGF is a clearly definable endpoint within this timeframe and that parameters measured as early as 1 month can reliably predict its development. This assumption is problematic. The development of sunset glow fundus represents a chronic depigmentary process associated with sustained choroidal inflammation and melanocyte loss, and it typically evolves gradually over time. In clinical practice, the diagnosis of true sunset glow fundus often requires longer-term observation beyond 12 months, particularly in patients who receive aggressive early immunosuppressive therapy. Therefore, categorizing patients as having or not having SGF at 12 months may lead to misclassification, especially in cases with delayed or subclinical progression.

2) It is even more problematic to conceptually link parameters measured at 1 month to the definitive occurrence of sunset glow fundus. At 1 month after treatment initiation, patients are still in the early recovery phase of acute VKH, and inflammatory activity may fluctuate depending on treatment response, tapering schedule, and individual immune dynamics. It is therefore unrealistic to assume that a single measurement at this time point can serve as a reliable predictor of a chronic structural outcome such as sunset glow fundus. The temporal gap between early inflammatory changes and late depigmentary manifestations is biologically complex and cannot be reduced to a simple predictive relationship without careful longitudinal validation.

3) The manuscript does not provide a sufficiently rigorous definition of sunset glow fundus. It is unclear whether the diagnosis was based solely on color fundus photography, clinical judgment, or standardized criteria incorporating multimodal imaging such as fundus autofluorescence or indocyanine green angiography. Without explicit diagnostic criteria, the reliability and reproducibility of SGF classification remain uncertain. This is particularly important given that subtle depigmentary changes may be misinterpreted or overlooked, especially in the early stages.

4) Another issue relates to the statistical interpretation of the predictive model. The reported Youden index values for both BCVA and corneal thickness are below 0.3, indicating limited discriminatory ability. Indeed, the sensitivity values for both predictors are less than 0.5, as shown in Table 3 of the manuscript. These findings suggest that the proposed predictors have weak clinical utility, and the manuscript should explicitly acknowledge this limitation. Presenting these parameters as “key risk factors” may overstate their practical relevance.

5) The biological plausibility of corneal thickness as a predictor of sunset glow fundus also requires further discussion. While the authors suggest that corneal morphology may reflect inflammatory activity, the mechanistic link between corneal thickness and choroidal melanocyte loss is indirect at best. It is possible that corneal thickness represents a nonspecific marker of systemic or ocular inflammation rather than a disease-specific predictor. This distinction should be clarified.

6) Another important issue relates to the influence of treatment intensity on the long-term course of Vogt–Koyanagi–Harada (VKH) disease and the development of chronic depigmentary changes such as sunset glow fundus. The current manuscript focuses on predictive factors measured at 1 month after pulse steroid therapy; however, it does not sufficiently discuss how the initial treatment regimen itself may affect disease outcomes. It is now well recognized that the adequacy of early immunosuppression plays a critical role in preventing chronic evolution of VKH. In this context, the authors should cite and discuss the recent study by Tsubota et al., which directly compared the efficacy and safety of full-dose pulse versus half-pulse steroid therapy in VKH disease (Tsubota K, et al. Comparative study of efficacy and safety of pulse versus half-pulse steroid therapy for Vogt-Koyanagi-Harada Disease. Jpn J Ophthalmol. 2025;69:805–812). That study demonstrated that differences in initial steroid dosing strategies can significantly influence clinical outcomes, highlighting the importance of treatment-related variables in determining long-term disease progression.

Failure to account for variations in treatment intensity may confound the interpretation of predictive factors identified in the present study. Therefore, incorporation of this reference into the Introduction and Discussion sections would strengthen the scientific context and improve the clinical relevance of the manuscript.

7) From a clinical standpoint, the study would be strengthened by extending the follow-up period and evaluating SGF development at later time points, such as 18 or 24 months. Alternatively, the authors could redefine the outcome as “early depigmentary change” or “risk of chronic evolution” rather than definitive sunset glow fundus. Such terminology would better reflect the biological trajectory of VKH disease.

8) The manuscript would benefit from a clearer discussion of treatment-related variables. The tapering schedule of corticosteroids, the use of additional immunosuppressive agents, and the timing of therapy escalation are all factors known to influence chronic progression and SGF development. Without accounting for these variables, it is difficult to interpret the observed associations.

Reviewer #2: Despite the merit of this manuscript, the current form has multiple flaws should therefore be revised before it can be accepted.

Youden Index Discrepancies: The Abstract states that the Youden index for both BCVA and corneal thickness is 0.291. However, Table 3 reports a Youden index of 0.244 for corneal thickness. These values must be reconciled.

Contradictory Significance Labels: In the Results section, the authors report that RFT and CFT decreased significantly (p<0.001). Conversely, the legends for Figure 2 (k and l) state these changes occurred "without significant differences." This contradiction undermines the credibility of the findings.

Failure to Account for Inter-eye Correlation: The study analyzes 121 eyes from 61 patients. Because the two eyes of a single patient are highly correlated, treating them as independent samples in t-tests or ANOVA is statistically inappropriate. The authors must re-analyze the data using Generalized Estimating Equations (GEE) or Linear Mixed Models (LMM) to account for this clustering.

Logical Flaw in Exclusion Criteria: The manuscript lists "high myopia (greater than -8 diopters)" as an exclusion criterion. Clinically and mathematically, high myopia involves values less than -8D (e.g., -9D, -10D). Using "greater than" implies the exclusion of mild myopia, which appears to be a typographical or logical error.

Redundancy: In the multivariable analysis description, "ACV" (anterior chamber volume) is listed twice.

**********

what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review?  For information about this choice, including consent withdrawal, please see our Privacy Policy

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures

You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation.

NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications.

PLoS One. 2026 Nov 11;21(11):e0362558. doi: 10.1371/journal.pone.0362558.r002

Author response to Decision Letter 1


17 Jun 2026

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

Yes, we revised headings in Bold type, 18pt font.

2. Thank you for stating the following in the Acknowledgments Section of your manuscript:

“The authors received no external funding or financial support.”

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

“The author(s) received no specific funding for this work.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

Yes, we removed funding-related text from the manuscript as below.

Funding declaration

The authors received no external funding or financial support.

3. Please include a separate caption for each figure in your manuscript.

Yes, we included a separate caption for each figure in our manuscript.

4. We note that Figure 1 in your submission contain copyrighted images. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For more information, see our copyright guidelines: http://journals.plos.org/plosone/s/licenses-and-copyright.

We require you to either (1) present written permission from the copyright holder to publish these figures specifically under the CC BY 4.0 license, or (2) remove the figures from your submission:

Yes, we removed the figure 1 from our submission. According to this revision, we deleted a below paragraph from results.

Fig. 1 illustrates PentacamⓇ measurements at 1 month and color fundus images at 12 months post-treatment for the SGF and non-SGF groups. Increased corneal thickness, as indicated by “Pachy” in the figures, is observed in association with SGF development.

1. You may seek permission from the original copyright holder of Figure(s) [#] to publish the content specifically under the CC BY 4.0 license.

We recommend that you contact the original copyright holder with the Content Permission Form (http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf) and the following text:

“I request permission for the open-access journal PLOS ONE to publish XXX under the Creative Commons Attribution License (CCAL) CC BY 4.0 (http://creativecommons.org/licenses/by/4.0/). Please be aware that this license allows unrestricted use and distribution, even commercially, by third parties. Please reply and provide explicit written permission to publish XXX under a CC BY license and complete the attached form.”

Please upload the completed Content Permission Form or other proof of granted permissions as an "Other" file with your submission.

In the figure caption of the copyrighted figure, please include the following text: “Reprinted from [ref] under a CC BY license, with permission from [name of publisher], original copyright [original copyright year].”

2. If you are unable to obtain permission from the original copyright holder to publish these figures under the CC BY 4.0 license or if the copyright holder’s requirements are incompatible with the CC BY 4.0 license, please either i) remove the figure or ii) supply a replacement figure that complies with the CC BY 4.0 license. Please check copyright information on all replacement figures and update the figure caption with source information. If applicable, please specify in the figure caption text when a figure is similar but not identical to the original image and is therefore for illustrative purposes only.

5. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

________________________________________

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: No

________________________________________

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

________________________________________

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

________________________________________

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This manuscript investigates predictive factors for the development of sunset glow fundus (SGF) in patients with Vogt–Koyanagi–Harada (VKH) disease, focusing on parameters measured at 1 month after pulse steroid therapy. The study includes a relatively well-defined cohort of treatment-naïve patients with at least 12 months of follow-up, and the attempt to identify early predictive indicators is clinically relevant. However, several conceptual and methodological concerns limit the validity of the conclusions. In particular, the definition and timing of SGF assessment raise important issues that must be addressed before the manuscript can be considered for publication.

1) The most critical concern relates to the diagnostic definition and temporal interpretation of sunset glow fundus. In this study, patients were classified into SGF and non-SGF groups based on fundus findings at 12 months after treatment initiation. However, the manuscript implicitly assumes that SGF is a clearly definable endpoint within this timeframe and that parameters measured as early as 1 month can reliably predict its development. This assumption is problematic. The development of sunset glow fundus represents a chronic depigmentary process associated with sustained choroidal inflammation and melanocyte loss, and it typically evolves gradually over time. In clinical practice, the diagnosis of true sunset glow fundus often requires longer-term observation beyond 12 months, particularly in patients who receive aggressive early immunosuppressive therapy. Therefore, categorizing patients as having or not having SGF at 12 months may lead to misclassification, especially in cases with delayed or subclinical progression.

Yes, we made a below paragraph in discussion.

The present study has several limitations. First, patients were classified into the SGF and non-SGF groups on the basis of fundus findings 12 months after treatment initiation. In clinical practice, a definitive diagnosis of SGF often requires observation beyond 12 months, particularly in patients who receive aggressive early immunosuppressive therapy. Therefore, classification of the SGF and non-SGF groups based on fundus findings obtained at a later time point may be more appropriate. Second, we assessed predictive factors at 1 month after pulse steroid therapy. At this stage, patients are still in the early recovery phase of acute VKH disease, and inflammatory activity may fluctuate depending on treatment response, the tapering schedule, and individual immune dynamics. Therefore, it may be unrealistic to assume that a single measurement obtained at this time point can serve as a reliable predictor of a chronic structural outcome such as SGF. Third, the Youden index values for both BCVA and corneal thickness were < 0.3, and the sensitivity values for both predictors were < 0.5, as shown in Table 3. These findings suggest that the proposed predictors have limited clinical utility. Fourth, corneal thickness may represent a nonspecific marker of systemic or ocular inflammation rather than a disease-specific predictor. It was not possible to distinguish between these possibilities in the present study.

Furthermore, we revised title and short title as below.

Predictive factors for risk of chronic evolution in Vogt–Koyanagi–Harada disease at 1 month after pulse steroid therapy

Short title: Predictive factors for risk of chronic evolution

2) It is even more problematic to conceptually link parameters measured at 1 month to the definitive occurrence of sunset glow fundus. At 1 month after treatment initiation, patients are still in the early recovery phase of acute VKH, and inflammatory activity may fluctuate depending on treatment response, tapering schedule, and individual immune dynamics. It is therefore unrealistic to assume that a single measurement at this time point can serve as a reliable predictor of a chronic structural outcome such as sunset glow fundus. The temporal gap between early inflammatory changes and late depigmentary manifestations is biologically complex and cannot be reduced to a simple predictive relationship without careful longitudinal validation.

Yes, we made a below paragraph in discussion.

The present study has several limitations. First, patients were classified into the SGF and non-SGF groups on the basis of fundus findings 12 months after treatment initiation. In clinical practice, a definitive diagnosis of SGF often requires observation beyond 12 months, particularly in patients who receive aggressive early immunosuppressive therapy. Therefore, classification of the SGF and non-SGF groups based on fundus findings obtained at a later time point may be more appropriate. Second, we assessed predictive factors at 1 month after pulse steroid therapy. At this stage, patients are still in the early recovery phase of acute VKH disease, and inflammatory activity may fluctuate depending on treatment response, the tapering schedule, and individual immune dynamics. Therefore, it may be unrealistic to assume that a single measurement obtained at this time point can serve as a reliable predictor of a chronic structural outcome such as SGF. Third, the Youden index values for both BCVA and corneal thickness were < 0.3, and the sensitivity values for both predictors were < 0.5, as shown in Table 3. These findings suggest that the proposed predictors have limited clinical utility. Fourth, corneal thickness may represent a nonspecific marker of systemic or ocular inflammation rather than a disease-specific predictor. It was not possible to distinguish between these possibilities in the present study.

3) The manuscript does not provide a sufficiently rigorous definition of sunset glow fundus. It is unclear whether the diagnosis was based solely on color fundus photography, clinical judgment, or standardized criteria incorporating multimodal imaging such as fundus autofluorescence or indocyanine green angiography. Without explicit diagnostic criteria, the reliability and reproducibility of SGF classification remain uncertain. This is particularly important given that subtle depigmentary changes may be misinterpreted or overlooked, especially in the early stages.

Yes, we added below sentences in materials and methods.

A single investigator (TM) assessed the ocular findings at approximately monthly intervals, and routinely determined the onset of SGF based on the appearance of the orange-red fundus discoloration that had not been present at the visit 1 month earlier. The presence of SGF in each eye was subsequently reconfirmed by reviewing the color fundus photographs.

4) Another issue relates to the statistical interpretation of the predictive model. The reported Youden index values for both BCVA and corneal thickness are below 0.3, indicating limited discriminatory ability. Indeed, the sensitivity values for both predictors are less than 0.5, as shown in Table 3 of the manuscript. These findings suggest that the proposed predictors have weak clinical utility, and the manuscript should explicitly acknowledge this limitation. Presenting these parameters as “key risk factors” may overstate their practical relevance.

Yes, we revised as below in abstract.

Elevated logarithmic BCVA values and increased corneal thickness at 1 month after treatment were identified as key risk factors for the subsequent SGF development.

Furthermore, we made a below paragraph in discussion.

The present study has several limitations. First, patients were classified into the SGF and non-SGF groups on the basis of fundus findings 12 months after treatment initiation. In clinical practice, a definitive diagnosis of SGF often requires observation beyond 12 months, particularly in patients who receive aggressive early immunosuppressive therapy. Therefore, classification of the SGF and non-SGF groups based on fundus findings obtained at a later time point may be more appropriate. Second, we assessed predictive factors at 1 month after pulse steroid therapy. At this stage, patients are still in the early recovery phase of acute VKH disease, and inflammatory activity may fluctuate depending on treatment response, the tapering schedule, and individual immune dynamics. Therefore, it may be unrealistic to assume that a single measurement obtained at this time point can serve as a reliable predictor of a chronic structural outcome such as SGF. Third, the Youden index values for both BCVA and corneal thickness were < 0.3, and the sensitivity values for both predictors were < 0.5, as shown in Table 3. These findings suggest that the proposed predictors have limited clinical utility. Fourth, corneal thickness may represent a nonspecific marker of systemic or ocular inflammation rather than a disease-specific predictor. It was not possible to distinguish between these possibilities in the present study.

5) The biological plausibility of corneal thickness as a predictor of sunset glow fundus also requires further discussion. While the authors suggest that corneal morphology may reflect inflammatory activity, the mechanistic link between corneal thickness and choroidal melanocyte loss is indirect at best. It is possible that corneal thickness represents a nonspecific marker of systemic or ocular inflammation rather than a disease-specific predictor. This distinction should be clarified.

Yes, we made a below paragraph in discussion.

The present study has several limitations. First, patients were classified into the SGF and non-SGF groups on the basis of fundus findings 12 months after treatment initiation. In clinical practice, a definitive diagnosis of SGF often requires observation beyond 12 months, particularly in patients who receive aggressive early immunosuppressive therapy. Therefore, classification of the SGF and non-SGF groups based on fundus findings obtained at a later time point may be more appropriate. Second, we assessed predictive factors at 1 month after pulse steroid therapy. At this stage, patients are still in the early recovery phase of acute VKH disease, and inflammatory activity may fluctuate depending on treatment response, the tapering schedule, and individual immune dynamics. Therefore, it may be unrealistic to assume that a single measurement obtained at this time point can serve as a reliable predictor of a chronic structural outcome such as SGF. Third, the Youden index values for both BCVA and corneal thickness were < 0.3, and the sensitivity values for both predictors were < 0.5, as shown in Table 3. These findings suggest that the proposed predictors have limited clinical utility. Fourth, corneal thickness may represent a nonspecific marker of systemic or ocular inflammation rather than a disease-specific predictor. It was not possible to distinguish between these possibilities in the present study.

6) Another important issue relates to the influence of treatment intensity on the long-term course of Vogt–Koyanagi–Harada (VKH) disease and the development of chronic depigmentary changes such as sunset glow fundus. The current manuscript focuses on predictive factors measured at 1 month after pulse steroid therapy; however, it does not sufficiently discuss how the initial treatment regimen itself may affect disease outcomes. It is now well recognized that the adequacy of early immunosuppression plays a critical role in preventing chronic evolution of VKH. In this context, the authors should cite and discuss the recent study by Tsubota et al., which directly compared the efficacy and safety of full-dose pulse versus half-pulse steroid therapy in VKH disease (Tsubota K, et al. Comparative study of efficacy and safety of pulse versus half-pulse steroid therapy for Vogt-Koyanagi-Harada Disease. Jpn J Ophthalmol. 2025;69:805–812). That study demonstrated that differences in initial steroid dosing strategies can significantly influence clinical outcomes, highlighting the importance of treatment-related variables in determining long-term disease progression.

Failure to account for variations in treatment intensity may confound the interpretation of predictive factors identified in the present study. Therefore, incorporation of this reference into the Introduction and Discussion sections would strengthen the scientific context and improve the clinical relevance of the manuscript.

Yes, we added below paper as reference no.8. According to this revision, Introduction was revised as below.

8. Tsubota K, Goto H, Asakage M, Kinoshita Y, Nonaka R, Wakatsuki K, et al. Comparative study of efficacy and safety of pulse versus half pulse steroid therapy for Vogt–Koyanagi–Harada disease. Jpn J Ophthalmol. 2025;69:805–812. doi: 10.1007/s10384-025-01213-3.

Vogt–Koyanagi–Harada (VKH) disease is a bilateral granulomatous panuveitis with potential multisystem involvement. It is a T-cell-mediated autoimmune disorder that occurs in genetically susceptible individuals, in which cytotoxic T-cells target melanocytes [1]. As melanocytes are widely distributed throughout the body, systemic manifestations such as fever meningitis-like symptoms, headache, paresthesia of hair, and general malaise often precede the onset of ocular symptoms. The disease can develop across a wide age range, from infancy to older adulthood, but is reported more frequently in females [2-8]. Adequate inhibition of inflammation during the early stage of the disease is important for preventing recurrence and the persistence of inflammation during later progressive stages.

In Japan, corticosteroid pulse therapy consisting of 500–1000 mg of intravenous methylprednisolone administered over 3 days, followed by several months of oral corticosteroids, has been widely implemented for many years [2-8].

Furthermore, we added a below paragraph in discussion.

It is now well recognized that adequate of early immunosuppression plays a critical role in preventing the chronic evolution of VKH disease. Tsubota et al. reported no significant difference in clinical efficacy between conventional pulse steroid therapy (1,000 mg/day of intravenous methylprednisolone for 3 days) and half-pulse steroid therapy (500 mg/day of intravenous methylprednisolone for 3 days) for VKH disease [8], concluding that half-pulse steroid therapy may reduce the risk of corticosteroid-related adverse effects [8]. They demonstrated that differences in initial steroid dosing strategies can significantly influence clinical outcomes, highlighting the importance of treatment-related variables in determining long-term disease progression [8]. Because pulse steroid therapy is associated with several adverse effects [21], their study is noteworthy in suggesting a strategy to reduce this risk [8].

7) From a clinical standpoint, the study would be strengthened by extending the follow-up period and evaluating SGF development at later time points, such as 18 or 24 months. Alternatively, the authors could redefine the outcome as “early depigmentary change” or “risk of chronic evolution” rather than definitive sunset glow fundus. Such terminology would better reflect the biological trajectory of VKH disease.

Yes, we revised title and short title as below.

Predictive factors for risk of chronic evolution in Vogt–Koyanagi–Harada disease at 1 month after pulse steroid therapy

Short title: Predictive factors for risk of chronic evolution

We revised last paragraph in introduction as below.

The aim of this study was to identify factors quantifiable at 1 month after pulse steroid therapy, as well as at the initial patient visit, that could predict the risk of chronic evolution 12 months post-treatment in patients with acute VKH disease.

Furthermore, we revised last paragraph in discussion as below.

In conclusion, this study identified two risk factors at 1 month post-treatment, along with their corresponding cut-off values, that are associated with the risk of chronic evolution. These findings may support more informed clinical decision-making in patients with VKH disease, particularly those presenting with BCVA and corneal thickness values exceeding the identified thresholds. Our future objectives include identifying more reliable predictive factors and establishing management strategies for cases exceeding the identified cut-off values.

8) The manuscript would benefit from a clearer discussion of treatment-related variables. The tapering schedule of corticosteroids, the use of additional immunosuppressive agents, and the timing of therapy escalation are all factors known to influence chronic progression and SGF development. Without accounting for these variables, it is difficult to interpret the observed associations.

Yes, we revised materials and methods as below.

Pulse steroid therapy was initiated with intravenous methylprednisolone (Solu-Medrol; Pfizer, NY, USA) at a dose of 1,000 mg/day for 3 days, followed by oral prednisolone (Predonine; Shionogi, Osaka, Japan). Oral prednisolone was started at 40 mg/day and tapered by 5 mg/day every 3 − 4 weeks, as previously described [2, 3]. Although one patient was 13 years old, her body weight (48 kg) allowed for the administration of the standard steroid regimen. Patients with recurrence limited to the anterior segment were treated with 0.1% fluorometholone ophthalmic suspension (Santen, Osaka, Japan) or Sanbetason ophthalmic and otorhinologic solution (Santen, Osaka, Japan). Patients with recurrence in the posterior segment were treated with oral corticosteroids or sub-Tenon triamcinolone acetonide injections. If anterior inflammation progressed to the chronic type and became resistant to steroid therapy, adalimumab was administered.

Reviewer #2: Despite the merit of this manuscript, the current form has multiple flaws should therefore be revised before it can be accepted.

Youden Index Discrepancies: The Abstract states that the Youden index for both BCVA and corneal thickness is 0.291. However, Table 3 reports a Youden index of 0.244 for corneal thickness. These values must be reconciled.

Yes, we revised a numerical value in abstract as below.

The corresponding Youden index values were 0.291 for BCVA and 0.244 for corneal thickness.

Contradictory Significance Labels: In the Results section, the authors report that RFT and CFT decreased significantly (p<0.001). Conversely, the legends for Figure 2 (k and l) state these changes occurred "without significant differences." This contradiction undermines the credibility of the findings.

Yes, we revised in the results section as below.

Both RFT and CFT decreased significantly over the observation period in both groups according to one-way repeated-measures ANOVA (p < 0.001) (Fig. 1 k, l).

We revised the legends for Figure 1 (k and l) as below.

(k) RFT at pretreatment and at 1, 6, and 12 months post-treatment, without significant differences according to the unpaired t-test. (l) CFT at pretreatment and at 1, 6, and 12 months post-treatment, with significant differences at pretreatment (p < 0.01), and 1 month (p < 0.05) according to the unpaired t-test.

Failure to Account for Inter-eye Correlation: The study analyzes 121 eyes from 61 patients. Because the two eyes of a single patient are highly correlated, treating them as independent samples in t-tests or ANOVA is statistically inappropriate. The authors must re-analyze the data using Generalized Estimating Equations (GEE) or Linear Mixed Models (LMM) to account for this clustering.

Yes, we re-analyzed the data using Generalized Estimating Equations (GEE) and made new Figure 2 (a~l).

Fig. 2 illustrates the chronological changes in mean biomarker values in both groups, as analyzed using GEEs. BCVA improved significantly over time in both groups (Fig. 2a). ACV (Fig. 2b) and central ACD values (Fig. 2c) also increased significantly over time in both groups. Peripheral ACD showed a similar pattern (Fig. 2d). ACA increased significantly in the non-SGF group remained largely unchanged in the SGF group (Fig. 2e). Pupil diameter (Fig. 2f) and corneal thickness (Fig. 2g) remained unchanged over time in both groups. SE decreased significantly in the SGF group, but showed minimal change in the non-SGF group (Fig. 2h). AL increased significantly in both groups (Fig. 2i). Lens thickness decreased significantly over time in the non-SGF group, but remained stable in the SGF group (Fig. 2j). Both RFT and CFT decreased significantly over the observation period in both groups according to the GEE analysis (p < 0.001) (Fig. 2k, l).

Fig. 2.

(a) Longitudinal changes in BCVA, as the logarithm of the minimum angle of resolution

for the SGF and non-SGF groups at pretreatment and at 1, 6, and 12 months post-treatment. A significant difference was observed at 1 month (p < 0.01). (b) ACV at pretreatment and at 1, 6, and 12 months post-treatment. without significant differences. (c) Central ACD at pretreatment and at 1, 6, and 12 months post-treatment. No significant differences were observed. (d) Peripheral ACD at pretreatment and at 1, 6, and 12 months post-treatment. No significant differences were observed. (e) ACA at pretreatment and at 1, 6, and 12 months post-treatment. No significant differences were observed. (f) Pupil diameter at pretreatment and at 1, 6, and 12 months post-treatment. No significant differences were observed. (g) Corneal thickness at pretreatment and at 1, 6, and 12 months post-treatment. Significant differences were observed at pretreatment (p < 0.001). (h) SE at pretreatment and at 1, 6, and 12 months post-treatment. No significant differences were observed. (i) AL at pretreatment and at 1, 6, and 12 months post-treatment. No significant differences were observed. (j) Lens thickness at pretreatment and at 1, 6, and 12 months post-treatment. No significant differences were observed. (k) RFT at pretreatment and at 1, 6, and 12 months post-treatment. No significant differences were observed. (l) CFT at pretreatment and at 1, 6, and 12 months post-treatment. No significant differences were observed.

Abbreviations: ACA, anterior chamber angle; ACD, anterior chamber depth; ACV, anterior chamber volume; AL, axial length; BCVA, best-corrected visual acuity; CFT, choroidal foveal thickness; RFT, retinal foveal thickness; SE, spherical equivalent.

Logical Flaw in Exclusion Criteria: The manuscript lists "high myopia (greater than -8 diopters)" as an exclusion criterion. Clinically and mathematically, high myopia involves values less than -8D (e.g., -9D, -10D). Using "greater than" implies the exclusion of mild myopia, which appears to be a typographical or logical error.

Yes, we revised as below.

high myopia (less than -8 diopters)

Redundancy: In the multivariable analysis description, "ACV" (anterior chamber volume) is listed twice.

Yes, we revised as below.

These outcomes included BCVA, ACV, ACD (also peripheral), corneal thickness, SE and changes in these parameters from the initial visit to 1 month, ACV, difference of ACV from initial visit to 1 month post-treatment, as well as ACA, pupil diameter, AL, RFT, and CFT.

________________________________________

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

________________________________________

Attachment

Submitted filename: Response to Reviewers.docx

pone.0362558.s002.docx (273.6KB, docx)

Decision Letter 1

Robin Haunschild

8 Sep 2026

Dear Dr. Muto,

Thank you for submitting your manuscript to PLOS One. After careful consideration, we feel that it has merit but does not fully meet PLOS One’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Oct 23 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

  • A letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS One offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only  the individual author can complete the verification step; PLOS staff cannot  verify ORCID iDs on behalf of authors.

We look forward to receiving your revised manuscript.

Kind regards,

Robin Haunschild

Academic Editor

PLOS One

Journal Requirements:

If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

Reviewer #2: All comments have been addressed

Reviewer #3: (No Response)

**********

2. Is the manuscript technically sound, and do the data support the conclusions??>

Reviewer #2: Yes

Reviewer #3: Partly

**********

3. Has the statistical analysis been performed appropriately and rigorously? -->?>

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available??>

The PLOS Data policy

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #2: Yes

Reviewer #3: Yes

**********

Reviewer #2: The authors have addressed all the major issues of the original submission, and the current version is acceptable to be published.

Reviewer #3: Comments to the Authors:

The manuscript investigates early predictive factors for sunset glow fundus (SGF) development in patients with acute VKH disease. While the study addresses a clinically relevant question, several methodological and conceptual concerns must be addressed before the manuscript can be considered for publication.

Major Concerns:

1. Role of Extraocular Manifestations: The current study focuses exclusively on ocular parameters (anterior chamber morphology, BCVA, etc.). However, systemic manifestations, such as meningismus, tinnitus, dysacusis, and high sensitivity to touch of the hair, are frequently observed in VKH disease and have been strongly associated with disease progression. The authors should analyze the role of extraocular manifestations in their cohort as potential predictors for SGF. (PMID: 37058172; 17123618).

2. The manuscript does not clearly state which diagnostic criteria were used to classify the patients at the initial visit. While older criteria are traditionally common, recent literature has introduced updated diagnostic criteria for VKH disease that demonstrate significant advantages, notably a higher diagnostic sensitivity (PMID: 29978190). Please clarify the exact diagnostic criteria applied to this cohort in the Methods section.

3. The study cohort consists of 61 patients (121 eyes). It is unclear if this sample size provides sufficient statistical power to support the conclusions drawn from the multivariable analysis, particularly given the low sensitivity (<0.5) and Youden index (<0.3) values reported. Has a formal a priori sample size calculation or post hoc power analysis been performed? Please clarify this in the methodology.

**********

what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review?  For information about this choice, including consent withdrawal, please see our Privacy Policy

Reviewer #2: No

Reviewer #3: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures

You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation.

NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications.

Decision Letter 2

Robin Haunschild

27 Oct 2026

Predictive factors for risk of chronic evolution in Vogt–Koyanagi–Harada disease at 1 month after pulse steroid therapy

PONE-D-26-10226R2

Dear Dr. Muto,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Robin Haunschild

Academic Editor

PLOS One

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

Reviewer #3: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions??>

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously? -->?>

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available??>

The PLOS Data policy

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English??>

Reviewer #3: Yes

**********

Reviewer #3: I have carefully reviewed the manuscript and provided all my detailed comments and suggestions in the previous sections. I do not have any additional comments to add at this time. I believe the authors will carefully consider and address the points raised above.

**********

what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review?  For information about this choice, including consent withdrawal, please see our Privacy Policy

Reviewer #3: No

**********

Acceptance letter

Robin Haunschild

PONE-D-26-10226R2

PLOS One

Dear Dr. Muto,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS One and supporting open access.

Kind regards,

PLOS One Editorial Office Staff

on behalf of

Dr. Robin Haunschild

Academic Editor

PLOS One

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    Attachment

    Submitted filename: Response to Reviewers.docx

    pone.0362558.s002.docx (273.6KB, docx)
    Attachment

    Submitted filename: Response to reviewer.docx

    pone.0362558.s003.docx (26KB, docx)

    Data Availability Statement

    All relevant data are within the manuscript.


    Articles from PLOS One are provided here courtesy of PLOS

    RESOURCES